The role of epigenetics in environmental and occupational carcinogenesis

Chemico-Biological Interactions

Volumn 188, Issue 2, 2010, Pages 340-349

  Ziech, Dominique ^a   Franco, Rodrigo ^b   Pappa, Aglaia ^c   Malamou Mitsi, Vasiliki ^d   Georgakila, Stavroula ^e,f   Georgakilas, Alexandros G ^e   Panayiotidis, Mihalis I ^a,d  

^a UNIVERSITY OF NEVADA   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

^e EAST CAROLINA UNIVERSITY   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarkers; Cancer diagnostics; Cancer therapies; DNA methylation; Environmental carcinogenesis; Epigenetics; Occupational carcinogenesis

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; 5 METHYLCYTOSINE; APC PROTEIN; AZACITIDINE; CADMIUM; CARCINOGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DIALLYL DISULFIDE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; EPIGALLOCATECHIN GALLATE; HISTONE; HISTONE DEACETYLASE INHIBITOR; HISTONE H2; HISTONE H3; MYC PROTEIN; NICKEL; PROTEIN MLH1; PROTEIN P16; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; REACTIVE OXYGEN METABOLITE; TOBACCO SMOKE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; AIR POLLUTANT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER RISK; CARCINOMA; CELL CYCLE ARREST; COLON CANCER; CPG ISLAND; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; EPIGENETICS; GENE DOSAGE; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; HUMAN; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTASIS; NEUROBLASTOMA; OCCUPATIONAL CARCINOGENESIS; OCCUPATIONAL EXPOSURE; ONCOGENE C MYC; ONCOGENE H RAS; OXIDATIVE STRESS; PROSTATE CANCER; PROTEIN MODIFICATION; REVIEW; SKIN CANCER; SMOKING; TESTIS CANCER; TUMOR SUPPRESSOR GENE; UBIQUITINATION; ANIMAL; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; CARCINOGENS, ENVIRONMENTAL; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; OCCUPATIONAL EXPOSURE;

EID: 77956649602     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.06.012     Document Type: Review

References (100)

1. Wogan G., Hecht S., Felton J., Conney A., Loeb L. Environmental and chemical carcinogenesis. Semin. Cancer Biol. 2004, 14:473-486.
2. Higginson J., Muir C.S. Determination of the importance of environmental factors in human cancer: the role of epidemiology. Bull. Cancer 1977, 64:365.
3. Clapp R., Howe G., Jacobs M. Environmental and occupational causes of cancer: a call to act on what we know. Biomed. Pharmacother. 2007, 61:631-639.
4. Harvard Cancer for Cancer Prevention, Causes of human cancer, Human report on cancer prevention, Cancer Causes Control, vol. 1, 1996, pp. S3-S59.
5. Irigaray P., Newby J.A., Clapp R., Hardell L., Howard V., Montagnier L., Epstein S., Belpomme D. Lifestyle-related factors and environmental agents causing cancer: an overview. Biomed. Pharmacother. 2007, 61:640-658.
6. Carpenter D., Arcaro K., Spink D. Understanding the human health effects of chemical mixtures. Environ. Health Perspect. 2002, 110:25-42.
7. Belpomme D., Irigaray P., Sasco A.J., Newby J.A., Howard V., Clapp R., et al. The growing incidence of cancer: role of lifestyle and screening detection. Int. J. Oncol. 2007, 30:1037-1049.
8. Belpomme D., Irigaray P., Hardell L., Clapp R., Montagnier L., Epstein S., et al. The multitude and diversity of environmental carcinogenesis. Environ. Res. 2007, 105:414-429.
9. Clapp R., Howe G., Jacob M. Environmental and occupational causes of cancer re-visited. J. Public Health Policy 2006, 27:61-76.
10. Zhang J., Smith K.R. Indoor air pollution: a global health concern. Br. Med. Bull. 2003, 68:209-225.
11. Vineis P., Hoek G., Krzyzanowski M., Vignia-Taglianti F., Vegalia F., Airoldi L., et al. Lung cancers attributable to environmental tobacco smoke and air pollution in non-smokers in different European countries: a prospective study. Environ. Health 2007, 6:7-13.
12. Dougherty C.P., Hendricks-Holtz S., Reinert J.C., Panyacosit L., Axelrad D.A., Woodruff T.J. Dietary exposures to food contaminants across the United States. Environ. Res. 2000, 84:170-185.
13. Beyersmann D., Hartwig A. Carcinogenic metal compounds: recent insight into molecular and cellular mechanisms. Arch. Toxicol. 2008, 82:493-512.
14. Szymanska-Chabowska A., Antonowica-Juchniewicz J., Andrzejak R. Some aspects of arsenic toxicity and carcinogenicity in living organism with special regard to its influence on cardiovascular system, blood and bone marrow. Int. J. Occup. Med. Environ. Health 2002, 15:101-116.
15. Galaris D., Evangelou A. The role of oxidative stress in mechanisms of metal-induced carcinogenesis. Crit. Rev. Oncol. Hematol. 2002, 42:93-103.
16. Leonard S., Bower J., Shi X. Metal-induced toxicity, carcinogenesis, mechanisms and cellular responses. Mol. Cell. Biochem. 2004, 255:3-10.
17. Franco R., Schoneveld O., Georgakilas A., Panayiotidis M. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett. 2008, 266:6-11.
18. Galaris D., Skiada V., Barbouti A. Redox signaling and cancer: the role of " labile iron" Cancer Lett. 2008, 266:21-29.
19. D. Hanahan, R. Weinberg R, The Hallmarks of cancer, Cell 100 (2000) 57-70.
20. M. Esteller, J. Herman, Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumors, J. Pathol. 196 (2002) 1-7.
21. Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 2007, 22:91-103.
22. Laird P.P. Cancer epigenetics. Hum. Mol. Genet. 2005, 14:R65-R76.
23. Nephew K., Huang T. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 2003, 190:125-133.
24. Estellel M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol. 2005, 45:629-656.
25. Costello J.F., Fruhwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., et al. Aberrant CpG-island methylation has non-random and tumor-type-specific patterns. Nat. Genet. 2000, 24:132-138.
26. El-Osta A. DNMT cooperativity-the developing links between methylation, chromatin structure and cancer. BioEssays 2003, 25:1071-1084.
27. Momparler R., Bovenzi V. DNA methylation and cancer. J. Cell Physiol. 2000, 183:145-154.
28. Jeltsch A. Beyond Watson and Crick: DNA methylation and molecular enzymology of DNA methyltransferases. Chem. Biol. Chem. 2002, 3:274-293.
29. Ehrlich M. DNA hypomethylation and cancer. DNA alterations in cancer: genetic and epigenetic changes 2000, 273-291. Eaton Publishing Bio Techniques Books, Natick, MA. M. Ehrlich (Ed.).
30. Hoffman M., Schultz W. Causes and consequences of DNA hypomethylation in human cancer. Biochem. Cell Biol. 2005, 83:296-321.
31. Kumar S., Cheng X., Klimasauskas S., Mi S., Posfai J., Roberts R., Wilson G. The DNA (cytosine-5) methyltransferases. Nucl. Acid Res. 1994, 22:1-10.
32. Turek-Plewa J., Jagodzinkski P. The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol. Biol. Lett. 2005, 10:631-647.
33. Hongpeng H., Lehming N. Global effects of histone modifications. Brief. Funct. Genomics Proteomics 2003, 2:234-243.
34. Santos-Rosa H., Schneider R., Bannister A.J., et al. Active genes are tri-methylated at K4 of histone H3. Nature 2002, 419:407-411.
35. Klaunig J.E., Kamendulis L.M., Xu Y. Epigenetic mechanisms of chemical carcinogenesis. Hum. Exp. Toxicol. 2000, 19:543-555.
36. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet 2003, 4:351-358.
37. Esteller M., Corn P.G., Baylin S.B., et al. A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61:3225-3229.
38. Esteller M., Cordon-Cardo C., Cirn P.G., et al. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res. 2001, 61:2816-2821.
39. Salnikow K., Zhitkovich A. Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic and chromium. Chem. Res. Toxicol. 2008, 21:28-44.
40. Risch A., Plass C. Lung cancer epigenetics and genetics. Int. J. Cancer 2008, 123:1-7.
41. Aochbauer-Muller S., Fong K.M., Virmani A.K., Geradts J., Gadzar A.F., Minna J.D. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001, 61:249-255.
42. Kersting M., Friedl C., Kraus A., Behn M., Pankow W., Schuerman M. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J. Clin. Oncol. 2003, 18:3221-3229.
43. Cho W. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol. Cancer 2007, 6:1-9.
44. Ushijima T., Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from?. Cancer Sci. 2005, 96:206-211.
45. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002, 21:5400-5413.
46. Florl A.R., Schulz W.A. Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells. Genes Chromosomes Cancer 2003, 37:141-148.
47. Cho B., Lee H., Jeong A., Bang Y.L., Lee H.J., Hwang K.S., et al. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant state of gastric carcinoma. Biochem. Biophys. Res. Commun. 2003, 307:52-63.
48. Ahmed F. Colorectal cancer epigenetics: the role of environmental factors and the search for molecular biomarkers. J. Environ. Sci. Health 2007, 25:101-154.
49. Barra J.L., Rhounim L., Rossignol J.L., Faugeron G. Histone H1 is dispensable for methylation-associated gene silencing in Ascobolus immerus and essential for long life span. Mol. Cell. Biol. 2000, 20:61-69.
50. Jason L.J., Moore S.C., Lewis J.D., et al. Histone ubiquitination: a tagging tail unfolds?. Bioessays 2002, 24:166-174.
51. Sakano K., Inagaki Y., Oikawa S., Hiraku Y., Kawanishi S. Copper-mediated oxidative DNA damage induced by eugenol: possible involvement of O-demethtylation. Mutat. Res. 2004, 565:35-44.
52. Hsiung D.T., Marsit C.J., Houseman E.A., Eddy K., Furniss C.S., McClean M.D., Kelsay K.T. Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 2007, 16:108-114.
53. Su S., Jin Y., Zhang W., Yang L., Shen Y., Cao Y., Tong J. Aberrant promoter methylation of p16(INK4a) and O(6)-methylguanine-DNA-methyltransferase genes in workers at a Chinese uranium mine. J. Occup. Health 2006, 48:261-266.
54. Kondo K., Takahashi Y., Hirose Y., Nagao T., Tsuyuguchi M., Hashimoto M., Ochiai A., Monden Y., Tangoku A. The reduced expression and aberrant methylation of p16(INK4a) in chromate workers with lung cancer. Lung Cancer 2006, 52:295-302.
55. Edwards T., Myers J. Environmental exposures and gene regulation in disease etiology. Environ. Health Perspect. 2007, 115:1264-1270.
56. Waisberg M., Joseph P., Hale B., Beyersmann D. Molecular and cellular mechanisms of cadmium carcinogenesis. Toxicology 2003, 192:95-117.
57. Huang D., Zhang Y., Qi Y., Chen C., Ji W. Global DNA hypomethylation, rather the reactive oxygen species (ROS), a potential facilitator of cadmium-stimulated K562 cell proliferation. Toxicol. Lett. 2008, 179:43-47.
58. Brama M., Gnessi L., Basciani S., Cerulli N., Politi L L., Spera G., Mariani S., Cherubini S., d'Abusco A.S., Scandurra R., Migliaccio S. Cadmium induces mitogenic signaling in breast cancer cell by an ER alpha-dependent mechanism. Mol. Cell. Endocrinol. 2007, 264:102-108.
59. Hengstler J.G., et al. Occupational exposure to heavy metals: DNA damage induction and DNA repair inhibition prove co-exposures to cadmium, cobalt and lead as more dangerous than hitherto expected. Carcinogenesis 2003, 24:63-73.
60. Achanzar W.E., Anchanzar K.B., Lewis J.G., Webber M.M., Waalkes M.P. Cadmium induces c-myc, p53, and c-jun expression in normal human prostate epithelial cells as a prelude to apoptosis. Toxicol. Appl. Pharmacol. 2000, 164:291-300.
61. Takiguchi M., Achanzar W.E., Qu W., Li G., Waalkes M.P. Effects of cadmium on DNA-(cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation. Exp. Cell Res. 2003, 286:355-365.
62. Lu H., Shi X., Costa M., Huang C. Carcinogenic effect of nickel compounds. Mol. Cell. Biochem. 2005, 279:45-67.
63. Golebiowki F., Kasprzak K.S. Inhibition of core histones acetylation by carcinogenic nickel (II). Mol. Cell. Biochem. 2005, 279:133-139.
64. Klein C.B., Conway K., Wang X.W., Bhamra R.K., Lin X.H., Cohen M.D., Annab L., Barrett J.C., Costa M. Senescence of nickel-transformed cells by an X chromosome possible epigenetic control. Science 1991, 251:796-799.
65. Broday L., Peng W., Kuo M.H., Salnikow K., Zoroddu M., Costa M. Nickel compounds are novel inhibitors of histone H4 acetylation. Cancer Res. 2000, 60:238-241.
66. Zoroddu M., Kowalik-Jankowaka T., Kozlowski H., Molinari H., Salnikow K., Broday L. Interaction of Ni (II) and Cu (II) with a metal binding sequence of histone: AKRHRK, a model of H4 tail. Biochem. Biophys. Acta 2001, 1475:163-168.
67. Aposhian H., Aposhian M.M. Arsenic toxicology: five questions. Chem. Res. Toxicol. 2006, 19:1-15.
68. S.M. Cohen, T. Ohnishi, L.L. Arnold, X. Le, Arsenic-induced bladder cancer in an animal model, Toxicol. Appl. Pharmacol. 222 (2007) 258-263.
69. Salnikow K., Cohen M.D. Backing into cancer: effects of arsenic on cell differentiation. Toxicol. Sci. 2002, 65:161-163.
70. Simeonova P.P., Luster M.I. Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms?. J. Environ. Pathol. Toxicol. Oncol. 2000, 9:281-286.
71. Cui X., Waiki T., Shirai Y., Hatakeyama K., Hirano S. Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. Toxicol. Sci. 2006, 91:372-381.
72. S. Chanda, U.B. Dasgupta, D. Guha-Mazumder, M. Gupta, U. Chaudhuri, S. Lahiri, S. Das, N. Ghosh, D. Chatterjee, DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy, Toxicol. Sci. 89 (2006) 431-437.
73. Paluszczak J., Baer-Dubowska W. Epigenetic diagnostics of cancer-the application of DNA methylation markers. J. Appl. Genet. 2006, 47:365-375.
74. Esteller M., Herman J.G. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004, 23:1-8.
75. Ushijima T T. Detection and interpretation of altered methylation patterns in cancer cells. Nature 2005, 5:223-232.
76. Board R., Lucy K., Greystoke A., Blackhall F., Hughes A., Dive C., Ranson M. DNA methylation in circulating tumor DNA as a biomarker for cancer. Biomarker Insights 2007, 2:307-319.
77. Cottrell S., Laird P.W. Sensitive detection of DNA methylation. Ann. N.Y. Acad. Sci. 2003, 983:102-130.
78. Brena R.M., Huang T., Plass C. Quantitative assessment of DNA methylation: potential applications for disease diagnosis, classification, and prognosis in clinical settings. J. Mol. Med. 2006, 84:365-377.
79. Miyamoto K., Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jpn. J. Clin. Oncol. 2005, 35:293-301.
80. W. Fischel, Y. Wang, C.D. Allis, Histone and chromatin cross talk, Curr. Opin. Cell Biol. 15 (2003) 172-183.
81. Fischel W., Wang Y., Allis C.D. Binary switches and modification cassettes in histone biology and beyond. Nature 2003, 425:475-479.
82. Freitas M., Sklenar A., Parthun M. Application of mass spectrometry to the identification and quantification of histone post-translational modifications. J. Cell Biochem. 2004, 92:9691-9700.
83. Balch C., Montgomery J., Paik H., Kim S., Huang T., Nephew K. New anti-cancer strategies: epigenetic therapies and biomarkers. Front. Biosci. 2005, 10:1897-1931.
84. Verma M., Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet 2002, 3:755-763.
85. Momparler R.L. Cancer epigenetics. Oncogene 2003, 22:6479-6483.
86. Kirk H., Cefalu W., Ribnicky D., Liu Z., Eilertsen J. Botanicals as epigenetic modulators for mechanism contributing to development of metabolic syndrome. Metab. Clin. Exp. 2008, 57:S16-S23.
87. Kim S.Y., Park K.W., Kim J.Y., Jeong I.Y., Byun M.W., Park J.E., et al. Thiosulfates from Allium tubersum L. induce apoptosis via caspase-dependent and -independent pathways in PC-3 human prostate cancer cells. Bioorg. Med. Chem. Lett. 2007, 18:199-204.
88. Hauser A.T., Jung M. Targeting epigenetic mechanisms: potential of natural products in cancer chemoprevention. Planta Med. 2008, 74:1593-1601.
89. Pina I.C., Gautschi J.T., Wang G.Y., Sanders M.L., Schmitz F.J., France D., et al. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem. 2003, 68:3866-3873.
90. Fang M.Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003, 63:7563-7570.
91. Narayanan B.A. Chemopreventive agents alter global gene expression pattern: predicting their mode of action and targets. Curr. Cancer Drug Targets 2006, 6:711-727.
92. Lee W.J., Zhu B.T. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 2006, 27:269-277.
93. Fang M.Z., Chen D., Sun Y., Jin Z., Christman J.K., Yang C.S. Reversal of hypermethylation and reactivation of p16INK4a, RAR beta, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 2005, 11:7033-7041.
94. Ungerstedt J.S., Sowa Y., Xu W.S., Shao Y., Dokmanovic M., Perez G., et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:673-678.
95. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 2005, 11:77-84.
96. Herman-Antosiewicz A., Singh A.V. Signal transduction pathways leading to cell cycle arrest and apoptosis induction in cancer cells by Allium vegetable-derived organosulfur compounds. Mutat. Res. 2004, 555:121-132.
97. Lea M.A., Rasheed M., Randolph V.M., Khan F., Shareef A., des Border C. Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S-allylmercaptocysteine. Nutr. Cancer 2002, 43:90-102.
98. Shirin H., Pinto J.T., Kawabata Y., Soh J.W., Delohery T., Moss S.F., et al. Anti-proliferative effects of S-allylmercaptocysteine on colon cancer cells when tested alone or in combination with sulindac sulfide. Cancer Res. 2001, 61:725-731.
99. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002, 1:287-299.
100. Budillon A., Di Gennaro E., Bruzzese F., Rocco M., Manzo G., Caraglia M. Histone deacetylase inhibitors: a new wave of molecular targeted anti-cancer agents. Recent Patents Anticancer Drug Discov. 2007, 2:119-134.